Current Issue
September 2016 Vol 9, No 6 - Business
A Matter of Trust
September 2016 Vol 9, No 6 - Clinical
Evaluating the True Value of High-Cost Therapies for Hepatitis C Infection
Most Popular Articles
June 2016 Vol 9, No 4 - Pipeline
February 2016 Vol 9, No 1 - Original Research
February 2016 Vol 9, No 1 - Industry Trends
March 2016, Vol 9, Seventh Annual Payers' Guide - Web Exclusive
July 2016 Vol 9, No 5 - Business
Editorial
September 2016 Vol 9, No 6 - Editorial
In ongoing work associated with the Jefferson College of Population Health (JCPH), I am engaged with a score of public and private sector organizations that are seeking to further define our field and to shape its future direction. I could not help but notice that in the past few weeks alone, in terms of consolidation, we have been at the “eye of the storm.” Allow me to share some specific examples of market consolidation, and then to offer some prognostication regarding the future.
Web Exclusives
The influence of genetics on the risk for type 2 diabetes has been suggested by previous research, but new research from the NIH has now outlined in unprecedented detail the role of common genetic variants in the risk for this disease. “Our study has taken us to the most complete understanding yet of the genetic architecture of type 2 diabetes,” said Michael Boehnke, PhD.
Featured Video
Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.
